Equities

Shanghai Serum Bio-Technology Co Ltd

688163:SHH

Shanghai Serum Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)14.78
  • Today's Change0.13 / 0.89%
  • Shares traded896.44k
  • 1 Year change-37.58%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Serum Bio-Technology Co Ltd is a China-based company mainly engaged in the research and development of antisera and antitoxins. The Company is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety. The Company's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The Company's products are mainly used for emergency snakebite treatment. The Company mainly conducts its businesses in the domestic market.

  • Revenue in CNY (TTM)192.49m
  • Net income in CNY37.23m
  • Incorporated1999
  • Employees321.00
  • Location
    Shanghai Serum Bio-Technology Co LtdNo. 1288, Huaqing Road, Qingpu DistrictSHANGHAI 201707ChinaCHN
  • Phone+86 2 164959122
  • Fax+86 2 164959122
  • Websitehttp://www.serum-china.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Rendu Biotechnology Co Ltd180.85m-8.77m1.35bn528.00--1.42--7.49-0.2192-0.21924.5223.780.16951.821.99342,521.40-0.8215---0.8869--70.19---4.85--13.78--0.008--3.95---63.89------
Shaanxi Kanghui Pharmaceutical Co Ltd588.60m-70.10m1.44bn828.00--1.46--2.44-0.7018-0.70185.899.840.2892.233.02710,868.00-4.511.41-6.351.7130.4145.74-15.604.480.8839-2.790.403432.3411.016.01-272.84--107.49--
Shanghai Rightongene Biotechnlgy Co Ltd265.52m7.17m1.44bn501.00194.101.55--5.440.13320.13324.7516.670.25401.091.40529,970.30-0.09014.16-0.0984.4975.0270.45-0.354811.6210.43--0.02845.90-39.142.84-80.41-11.4619.65--
Shanghai Serum Bio-Technology Co Ltd192.49m37.23m1.60bn321.0042.961.47--8.310.34410.34411.7810.050.16890.92826.82599,656.403.2710.433.3210.8475.0880.5419.3432.5750.03--0.011964.939.145.67-39.54-1.6213.07--
Shanghai Jiaoda Onlly Co Ltd280.54m-39.86m1.72bn935.00--5.90--6.13-0.0514-0.05140.3620.37610.34755.154.63300,042.20-4.64-7.62-7.62-10.7018.0340.06-13.36-27.010.6301-1.400.3455---21.432.6592.96---34.81--
Guangzhou LBP Medicine Scnc&Tech Co Ltd508.01m40.23m1.73bn907.0043.151.36--3.410.42920.42925.3213.610.37192.122.15560,104.201.835.101.915.5567.8375.154.9112.976.70--0.006824.42-1.9910.18-6.18-8.21-2.98--
Data as of May 17 2024. Currency figures normalised to Shanghai Serum Bio-Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

6.22%Per cent of shares held by top holders
HolderShares% Held
Gfund Management Co., Ltd.as of 31 Dec 2023664.54k2.68%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 2023547.90k2.21%
GF Fund Management Co., Ltd.as of 31 Dec 2023120.00k0.49%
China Asset Management Co., Ltd.as of 31 Dec 202380.90k0.33%
E Fund Management Co., Ltd.as of 30 Jun 202341.33k0.17%
Goldstate Capital Fund Management Co., Ltd.as of 30 Jun 202328.93k0.12%
Bank of China Investment Management Co., Ltd.as of 31 Dec 202325.57k0.10%
Fortune & Royal Asset Management Co., Ltd.as of 31 Dec 202310.41k0.04%
Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 20239.90k0.04%
CPIC Fund Management Co. Ltd.as of 31 Dec 20239.49k0.04%
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.